Назад к списку

The treatment of muscle-invasive urothelial carcinoma (MIUC) with adjuvant atezolizumab did not improve disease-free survival (DFS) compared with observation.

https://www.renalandurologynews.com/home/news/urology/bladder-cancer/urothelial-cancer-atezolizumab-adjuvant-treatment-risk-benefit/?utm_source=social&utm_medium=facebook&utm_content=15570ce6-a99c-48a1-b8df-a1e5164670b7&utm_campaign=run_daily_posts